Short term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: Comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist

Japanese Heart Journal

Volumn 44, Issue 5, 2003, Pages 693-704

  Koldas, Lale ^a,b   Ayan, Faruk ^a   Ikitimur, Baris ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Blood chemistry; Echocardiography; Left ventricular hypertrophy; Lipid profile; Rilmenidine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLORIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; PERINDOPRIL; POTASSIUM; RILMENIDINE; SODIUM; TRIACYLGLYCEROL; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD PRESSURE REGULATION; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SLOW RELEASE FORMULATION; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIASTOLE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OXAZOLES; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 3843132090     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.44.693     Document Type: Article

References (25)

1. Levy D, Garrison R J, Savage D, Kannel W, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
2. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
3. Safar M E. Rilmenidine : A novel antihypertensive agent. Am J Med 1989; 87: 24S-9S.
4. Trimarco B, Rosiello G, Sarno D, Lorino G, et al. Effects of one year treatment with rilmenidine on systemic hypertension induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol 1994; 74: 36A-42A.
5. Sadowski Z, Szwed H, Kuch-Wocial A, Kubasik A, et al. Regression of left ventricular hypertrophy in hypertensive patients after one year of treatment with rilmenidine. J Hypertens Suppl 1998; 16: S55-62.
6. Ostermann G, Brisgand B, Schmitt J, Fillastre JP. Efficacy and acceptability of rilmenidine for mild to moderate hypertension. Am J Cardiol 1998; 61: 76D-80D.
7. Franz IW, Ketelhut R, Behr U, Tonnesmann U. Time course of reduction in left ventricular mass during longterm antihypertensive therapy. J Hum Hypertens 1994; 8: 191-8.
8. Sehridan D. Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens 2000; 18: S21-7.
9. Kirkendall WM, Burton MC, Epstein FM, Frens ED. Recommendations for human blood pressure determinations by sphyngomanometers. Circulation 1967; 36: 980-8
10. Reichek N, Devereux RB. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic findings. Circulation 1981; 63: 1391-8.
11. Levy D, Wilson P W, Anderson K M, Castelli WP, et al. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Am Heart J 1990; 119: 712.
12. Tubau JF, Szlachcic J, Braun S, Massie BM. Impaired left ventricular function reserve in hypertensive patients with left ventricular hypertrophy. Hypertension 1989; 14: 1-8
13. Hartford M, Wilkstrand J, Wallenstin T, et al. Diastolic function of the heart in untreated primary hypertension. Hypertension 1994; 6: 329-38.
14. Strauer BE. Development of cardiac failure by coronary small vessel disease in hypertensive heart disease. J Hypertens 1991; 9: S11-21.
15. Messerli FH, Nunez ED, Nunez MM, et al. Hypertension and sudden death. Arch Intern Med 1989; 149: 1263-7.
16. Dominiac P. Historic aspects in the identification of the I1-receptor and the pharmacology of the imidazolines and blood pressure control. Boston/lodrecht/London, Kluwer Academic Publishers 1994: 21-30.
17. Bousquet P. Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol 1995; 26: S1-S6.
18. Beau B, Mahieux F, Paraire M, Laurin S, et al. Efficacy and safety of rilmenidine on arterial hypertension. Am J Cardiol 1998; 61: 95D-102D.
19. Scemama M, Fevrier B, Beucler I, Dairou F. Effects of rilmenidine on lipid balance in hyperlipidemic hypertensive patients. Ann Cardiol Angiol 1996; 45: 595-601.
20. Scemama M, Fevrier B, Beucler I, Dairou F. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. J Cardiovasc Pharmacol 1995; 26 suppl 2: S34-9.
21. De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, et al. Hemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. J Hypertens 2000; 18: 1515-22.
22. Gordon DJ, Protsfield JL, Garrison RJ, et al. High density lipoptotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
23. De Luca N, Izzo R, Fontana D, Ivino G, et al. Haemodynamic and metabolic effects in hypertensive patients with metabolic syndrome X. A double blind parallel study versus amlodipine. J Hypertens 2000; 18: 1515-22.
24. Yamakado T, Teramura S, Oonishi T, Maeda M, et al. Regression of left ventricular hypertrophy with long-term treatment of nifedipine in systemic hypertension. Clin Cardiol 1994; 17: 615-8.
25. Yalcin F, Aksoy FG, Muderrisoglu H, Sabah I, et al. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clin Cardiol 2000; 23: 437-41.